Aspire Biopharma Warrant
ASBPW
27 hedge funds and large institutions have $667K invested in Aspire Biopharma Warrant in 2025 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 4 closing their positions.
25% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 4
7% more capital invested
Capital invested by funds: $624K → $667K (+$42.5K)
4% more funds holding
Funds holding: 26 → 27 (+1)
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SC
Sculptor Capital
New York
|
+$115K |
| 2 |
AC
Aristeia Capital
Greenwich,
Connecticut
|
+$41K |
| 3 |
AIMCA
Alberta Investment Management Corp (AIMCo)
Edmonton,
Alberta, Canada
|
+$15.1K |
| 4 |
CS
Clear Street
New York
|
+$11.6K |
| 5 |
FTUS
Flow Traders U.S.
New York
|
+$854 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AA
AQR Arbitrage
Greenwich,
Connecticut
|
-$30.8K |
| 2 |
WAM
Wolverine Asset Management
Chicago,
Illinois
|
-$12.4K |
| 3 |
PC
Periscope Capital
Toronto,
Ontario, Canada
|
-$8.77K |
| 4 |
Nomura Holdings
Tokyo,
Japan
|
-$7.2K |
| 5 |
Walleye Trading
New York
|
-$621 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
OAC
26
OMERS Administration Corp
Toronto,
Ontario, Canada
| $1.82K | – | – | – |
|
|
FTUS
27
Flow Traders U.S.
New York
| $1K | +$854 | +14,191 | New |
|
|
RFA
28
Reyes Financial Architecture
San Diego,
California
| $4 | +$4 | +70 | New |
|
|
FFA
29
Farther Finance Advisors
San Francisco,
California
| $1 | +$1 | +10 | New |
|
|
AA
30
AQR Arbitrage
Greenwich,
Connecticut
| – | -$30.8K | -647,633 | Closed |
|
|
31
Nomura Holdings
Tokyo,
Japan
| – | -$7.2K | -150,000 | Closed |
|
|
32
Walleye Trading
New York
| – | -$621 | -13,076 | Closed |
|
ASBPW Hedge Fund Activity: Q1 2025 in Review
27 of the 7,462 institutional investors tracked by Wall St. Rank reported a position in Aspire Biopharma Warrant (ASBPW) for Q1 2025, worth a combined $667K — up 6.8% from $624K a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new ASBPW positions and 4 closed out — a net gain of 1 holder — while 2 added to existing stakes and 2 trimmed.
The largest buyer was Sculptor Capital, adding an estimated $115K. The largest seller was AQR Arbitrage, exiting entirely with an estimated $30.8K sold.
- 27 institutional investors held Aspire Biopharma Warrant (ASBPW) as of Q1 2025, up from 26 in Q4 2024.
- Funds reported $667K of Aspire Biopharma Warrant stock for Q1 2025, up 6.8% quarter-over-quarter.
- 5 funds opened new Aspire Biopharma Warrant positions in Q1 2025 and 4 closed out, a net change of +1 holder.
- The largest Aspire Biopharma Warrant buyer in Q1 2025 was Sculptor Capital, an estimated $115K added.
- The largest Aspire Biopharma Warrant seller in Q1 2025 was AQR Arbitrage, an estimated $30.8K sold.
Based on aggregated 13F filings for Q1 2025.